Conference call and webcast: today,
March 9, 2023, 9:00 am ET
REHOVOT, Israel, March 9,
2023 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN)
(TASE: EVGN), a leading computational biology company targeting to
revolutionize life-science based product discovery and development
utilizing cutting edge computational biology technologies, across
multiple market segments, today announced its financial results for
the fourth quarter and full year period ending December 31, 2022.
Mr. Ofer Haviv, Evogene's
President and Chief Executive Officer, stated, "We are very
proud of the achievements made by Evogene and its subsidiaries in
the past year. Throughout 2022, we made progress and have advanced
the artificial-intelligence technology underlying our tech engines
which are MicroBoost AI supporting the discovery and
development of microbe-based products, ChemPass AI
supporting small-molecule based products and GeneRator
AI supporting products based on modifying genetic
elements."
"Lavie Bio, our subsidiary
focused on developing and commercializing microbiome-based
ag-biological products, leveraging Evogene's MicroBoost AI
tech-engine, has not only seen progress in 2022, but also received
external validation of its value, via a $10
million SAFE investment and strategic collaboration with
ICL, a leading global specialty mineral and ag-tech company. In
spring 2022, Lavie Bio saw initial
sales and revenue from ThrivusTM, our inoculant product
for spring wheat, which is a combination of bacterial strains which
improve nutrient availability and uptake, improving plant health
and we expect sales to be significantly expanded in the 2023 spring
season. Furthermore, Lavie Bio's
product development pipeline continues to advance. Throughout 2022,
we conducted a number of successful field trials for our
bio-fungicide products with positive results and in October 2022, we submitted the registration to
the U.S. Environmental Protection Agency for our novel
bio-fungicide LAV311 product, targeting fruit rots and mildews,
which is a final step prior to the commercialization of LAV311 in
the US."
"Another external validation to the value contained within our
subsidiaries and now becoming more apparent is through an
investment in Biomica, our subsidiary developing
microbiome-based therapeutics for the treatment of immune-mediated
and infectious diseases, leveraging Evogene's MicroBoost AI
tech-engine. It is a vote of confidence from leading Chinese
private equity fund, Shanghai Healthcare Capital ("SHC"), the lead
investor of a $10 million seed
investment round into Biomica, at a post money valuation of
$50 million. This external and
independent endorsement of Biomica, validates our belief in
Biomica's long-term potential to achieve its targets. In terms of
its product pipeline, Biomica continues to advance its phase-I
clinical trial for its microbiome-based immuno-oncology drug
candidate, with results expected later in 2023. Biomica's IBD
(inflammatory bowel disease) program, completed the pre-clinical
phase successfully and aims to progress to a phase-1 US clinical
trial. Biomica's third program for IBS (irritable bowel syndrome),
has completed the discovery-phase in 2022 and is progressing into a
pre-clinical phase."
"Our subsidiary AgPlenus has a goal to discover new
mode-of-action crop protection products including herbicides,
insecticides and fungicides, leveraging our ChemPass AI
tech-engine. AgPlenus continues to work closely with Corteva,
already under a three-year collaboration agreement, to develop new
mode-of-action herbicides to target resistant weeds and we look to
broadening AgPlenus' collaboration to other major global players.
The most advanced program within the internal product pipeline,
focuses on the target protein APH1, representing a novel
mode-of-action for herbicides, aiming to provide broad spectrum
weed control. In 2022, we achieved our milestone in this program to
expand its data package as preparation for potential license
agreements. We see strong market interest from the major ag-tech
companies for our products in the pipeline and especially for our
unique technology, which we aim to materialize into additional
collaboration agreements."
"Following our recent generation-2 product launch and
commercialization, Canonic, our subsidiary that has
developed attractive medical cannabis products, using Evogene's
GeneRator AI tech-engine to select genes to provide maximal
levels of THC and unique terpenes profiles, is seeing increasing
sales. At the same time, we understand the global cannabis market
has become increasingly competitive during the past year and we
don't expect that situation to change in the near term. While we
are continuing to support Canonic's growth, we have made some
recent structural changes to lower expenses and we are considering
various longer-term options."
"Finally, Casterra is a subsidiary that was established
many years ago focused on developing castor seeds for biofuel and
leveraging Evogene's GeneRator AI tech-engine. We always
held a long belief in the advantages of castor as a bioenergy and
biopolymer source. While our activities in this arena were somewhat
dormant in recent years, the biofuel industry is finally beginning
to follow our vision that castor oil can serve as a source for
bio-diesel and we have seen a great recent resurgence in interest.
Our technology not only produces an energy-dense seed, we have also
created a plant tailored specifically for efficient mechanized
harvesting, previously a hurdle limiting the use of castor.
Casterra recently signed an agreement with one of the world's
leading energy companies based in Europe, selling them our seeds for growing
castor to be used as biofuel in Africa. We have built a strong relationship
with our EU partner, and hope to expend the scope of our engagement
in the coming years."
"Not only have we seen strong success in 2022, but it has been
validated by major external players by their investments. It ties
their interests with ours into the long-term growth and value
potential of our subsidiary companies. This is a substantial
validation of all our hard work and our collective achievements to
date, and demonstrates significant credibility of the value that
Evogene's AI tech-engines provide."
Consolidated Financial Results Summary
Cash position: Evogene continues to maintain a solid
financial position for its activities with approximately
$35 million in consolidated cash,
cash equivalents and marketable securities as of December 31, 2022. This amount does not include
the $10 million investment to Biomica
by SHC that is expected to be closed in the coming weeks.
Approximately $9.7 million of
Evogene's consolidated cash is appropriated to its subsidiary,
Lavie Bio.
During the fourth quarter, the consolidated cash usage was
approximately $2.6 million, or
approximately $0.4 million, excluding
Lavie Bio. For 2022 as a whole, the
consolidated cash usage was approximately $28.5 million, or approximately $20.0 million, excluding Lavie Bio. The consolidated cash usage for 2022
included financing expenses in the amount of $2.3 million due to U.S. Dollar and New Israeli
Shekel exchange rate differences and a decrease in the market value
of marketable securities in the amount of $0.8 million.
Revenues: Revenues for the fourth quarter of 2022 were
$660 thousand, in comparison to
$311 thousand in the same period the
previous year. Revenues for the full year 2022 were $1.7 million, in comparison to $0.9 million in 2021. The increase in revenues
was primarily due to revenues recognized per the collaboration
agreement of Evogene's subsidiary AgPlenus with Corteva, as well as
revenues from sales of Canonic's medical cannabis products in
Israel.
R&D expenses for the fourth quarter of 2022, which
are reported net of non-refundable grants received, were
$4.8 million, in comparison to
$6.0 million in the same period in
the previous year. For the full year 2022, these expenses were
$20.8 million, in comparison to
$21.1 million in 2021. The main
contributors to R&D expenses were Lavie
Bio's activities supporting the production and
commercialization of its inoculant product Thrivus™, Evogene's
ongoing development of its technology engines and Biomica's
microbiome-based therapeutics development efforts.
Sales and marketing expenses were approximately
$1.2 million for the fourth quarter
of 2022, in comparison to $0.7
million in the same period the previous year. For the full
year 2022, these expenses were $3.9
million, in comparison to $2.7
million in 2021. The increase was mainly due to Lavie Bio's increased business development
personnel and commercial trials of its inoculant product, Thrivus™,
performed during 2022 and increased business development personnel
in Canonic.
General and Administrative expenses were $1.7 million in the fourth quarter of 2022, in
comparison to $2.0 million in the
same period in the previous year. For the full year 2022, these
expenses were $6.5 million, in
comparison to $7.3 million in 2021.
The decrease was mainly attributed to the decrease of the costs of
directors' and officers' insurance, and to the decrease of
share-based compensation expenses.
Other income was $3.5
million in the fourth quarter and full year of 2022. This
was received from Bayer under their joint seed traits collaboration
agreement with Evogene, as part of a restructuring and release of
the patent filing, prosecution, and maintenance obligations under
the collaboration.
Operating loss: Operating loss for the fourth quarter of
2022 was $3.8 million, in comparison
to $8.7 million in the same period in
the previous year. Operating loss for the full year 2022 was
$26.9 million, in comparison to
$31.0 million in 2021. The decrease
in operating loss is mainly due to the other income received
from Bayer, as described above.
Financing income for the fourth quarter of 2022 was
$6 thousand, in comparison to
financing income of $602 thousand in
the same period in the previous year. Financing expenses for the
full year 2022 were $2.8 million, in
comparison to financing income of $0.5
million in 2021. The difference between periods was mainly
due to U.S. Dollar and New Israeli Shekel exchange rate differences
between periods, and a change in the value of marketable
securities.
Net loss: Net loss for the fourth quarter of 2022 was
$3.8 million, in comparison to a net
loss of $8.1 million in the same
period in the previous year. Net loss for the full year 2022 was
$29.8 million, in comparison to a
loss of $30.4 million for 2021.
Conference Call & Webcast Details:
Date: March 9, 2022
Time: 9:00 am ET; 16:00
Israel time
Dial-in numbers:1-888-281-1167 toll free from
the United States, or
+972-3-918-0609 internationally
Webcast & Presentation link available at:
https://www.evogene.com/investor-relations/presentations-and-webcasts/
The Company's investor presentation can be viewed at the above
link, which is in the investor relations section of the company
website.
Replay Information: A replay of the conference call will
be available approximately two hours following the completion of
the call.
To access the replay, please dial 1-888-326-9310 toll free from
the United States, or
+972-3-925-5901 internationally. The replay will be accessible
following the call for three days. An archive of the webcast will
be available on the Company's website.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN) (TASE: EVGN) is a computational biology
company aiming to revolutionize the development of life-science
based products by utilizing cutting-edge technologies to increase
the probability of success while reducing development time and
cost. Evogene established three unique tech-engines – MicroBoost
AI, ChemPass AI and GeneRator AI – leveraging Big
Data and Artificial Intelligence and incorporating deep
multidisciplinary understanding in life sciences. Each tech-engine
is focused on the discovery and development of products based on
one of the following core components: microbes (MicroBoost
AI), small molecules (ChemPass AI), and genetic elements
(GeneRator AI).
Evogene uses its tech-engines to develop products through
subsidiaries and strategic partnerships. Evogene's subsidiaries
currently utilize the tech-engines to develop human
microbiome-based therapeutics by Biomica, ag-biologicals by
Lavie Bio, ag-chemicals by AgPlenus,
medical cannabis products by Canonic and castor varieties, for the
biofuel and other industries, by Casterra.
Forward Looking Statements
This press release contains "forward-looking statements"
relating to future events. These statements may be identified by
words such as "may", "could", "expects", "hopes" "intends",
"anticipates", "plans", "believes", "scheduled", "estimates" or
words of similar meaning. For example, Evogene is using
forward-looking statement in this press release when it discusses
the growth and value potential in its subsidiaries, the scope for
expansion and revenue growth in the coming years for Casterra,
potential advancements in the pipeline and collaborations for
AgPlenus, increased revenue and lower expenses for Canonic during
2023, expansion of sales of Thrivus in 2023 and advancement of
Lavie Bio's product development
pipeline and the timing and results of the clinical trials and
pre-clinical trials of Biomica's products. Such statements are
based on current expectations, estimates, projections and
assumptions, describe opinions about future events, involve certain
risks and uncertainties which are difficult to predict and are not
guarantees of future performance. Therefore, actual future results,
performance or achievements of Evogene and its subsidiaries may
differ materially from what is expressed or implied by such
forward-looking statements due to a variety of factors, many of
which are beyond the control of Evogene and its subsidiaries,
including, without limitation, those risk factors contained in
Evogene's reports filed with the applicable securities authority.
In addition, Evogene and its subsidiaries rely, and expect to
continue to rely, on third parties to conduct certain activities,
such as their field-trials and pre-clinical studies, and if these
third parties do not successfully carry out their contractual
duties, comply with regulatory requirements or meet expected
deadlines, Evogene and its subsidiaries may experience significant
delays in the conduct of their activities. Evogene and its
subsidiaries disclaim any obligation or commitment to update these
forward-looking statements to reflect future events or developments
or changes in expectations, estimates, projections and
assumptions.
Evogene Investor Contact
Kenny Green, Investor
Relations
E: kenny.green@evogene.com
T: +1 212 378 8040
CONSOLIDATED
STATEMENTS OF FINANCIAL POSITION
|
U.S. dollars in
thousands (except share and per share data)
|
|
|
|
|
December
31,
|
|
December
31,
|
|
|
2022
|
|
2021
|
|
|
(Unaudited)
|
|
(Audited)
|
CURRENT
ASSETS:
|
|
|
|
|
Cash and cash
equivalents
|
|
$ 28,980
|
|
$ 32,325
|
Short-term bank
deposits
|
|
-
|
|
3,000
|
Marketable
securities
|
|
6,375
|
|
18,541
|
Trade
receivables
|
|
348
|
|
281
|
Other receivables and
prepaid expenses
|
|
1,482
|
|
2,651
|
Inventories
|
|
566
|
|
92
|
|
|
|
|
|
|
|
37,751
|
|
56,890
|
LONG-TERM
ASSETS:
|
|
|
|
|
Long-term deposits and
other receivables
|
|
74
|
|
25
|
Deferred
taxes
|
|
94
|
|
-
|
Right-of-use-assets
|
|
1,568
|
|
2,109
|
Property, plant and equipment, net
|
|
2,499
|
|
2,073
|
Intangible assets,
net
|
|
14,140
|
|
15,207
|
|
|
|
|
|
|
|
18,375
|
|
19,414
|
|
|
|
|
|
|
|
$ 56,126
|
|
$
76,304
|
CURRENT
LIABILITIES:
|
|
|
|
|
Trade
payables
|
|
$
1,036
|
|
$
1,463
|
Employees and payroll
accruals
|
|
1,987
|
|
2,662
|
Lease
liability
|
|
884
|
|
974
|
Liabilities in respect
of government grants
|
|
79
|
|
89
|
Deferred revenues and
other advances
|
|
22
|
|
175
|
Other
payables
|
|
1,617
|
|
1,519
|
|
|
|
|
|
|
|
5,625
|
|
6,882
|
LONG-TERM
LIABILITIES:
|
|
|
|
|
Lease
liability
|
|
932
|
|
1,695
|
Liabilities in respect
of government grants
|
|
4,665
|
|
4,307
|
Convertible
SAFE
|
|
10,114
|
|
-
|
|
|
|
|
|
|
|
15,711
|
|
6,002
|
SHAREHOLDERS'
EQUITY:
|
|
|
|
|
Ordinary shares of NIS
0.02 par value:
Authorized –
150,000,000 ordinary shares; Issued and outstanding
–41,260,439 shares on December 31, 2022 and 41,170,168
shares
on December 31, 2021
|
|
235
|
|
234
|
Share
premium and other capital reserve
|
|
261,402
|
|
260,488
|
Accumulated
deficit
|
|
(233,707)
|
|
(207,069)
|
|
|
|
|
|
Equity
attributable to equity holders of the Company
|
|
27,930
|
|
53,653
|
|
|
|
|
|
Non-controlling
interests
|
|
6,860
|
|
9,767
|
|
|
|
|
|
Total
equity
|
|
34,790
|
|
63,420
|
|
|
|
|
|
|
|
$ 56,126
|
|
$
76,304
|
CONSOLIDATED
STATEMENTS OF PROFIT OR LOSS
|
U.S. dollars in
thousands (except share and per share data)
|
|
|
|
|
|
|
|
|
Year
ended
December
31,
|
|
Three months
ended
December
31,
|
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
|
|
(Unaudited)
|
|
(Audited)
|
|
(Unaudited)
|
|
|
|
|
|
|
|
|
|
Revenues
|
|
$
1,675
|
|
$
930
|
|
$ 660
|
|
$ 311
|
Cost of
revenues
|
|
909
|
|
767
|
|
364
|
|
267
|
|
|
|
|
|
|
|
|
|
Gross profit
|
|
766
|
|
163
|
|
296
|
|
44
|
|
|
|
|
|
|
|
|
|
Operating expenses
(income):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and
development, net
|
|
20,792
|
|
21,125
|
|
4,753
|
|
6,016
|
Sales and
marketing
|
|
3,933
|
|
2,738
|
|
1,168
|
|
720
|
General and
administrative
|
|
6,482
|
|
7,253
|
|
1,657
|
|
2,000
|
Other
income
|
|
(3,500)
|
|
-
|
|
(3,500)
|
|
-
|
|
|
|
|
|
|
|
|
|
Total operating
expenses, net
|
|
27,707
|
|
31,116
|
|
4,078
|
|
8,736
|
|
|
|
|
|
|
|
|
|
Operating
loss
|
|
(26,941)
|
|
(30,953)
|
|
(3,782)
|
|
(8,692)
|
|
|
|
|
|
|
|
|
|
Financing
income
|
|
516
|
|
1,935
|
|
169
|
|
938
|
Financing
expenses
|
|
(3,329)
|
|
(1,414)
|
|
(163)
|
|
(336)
|
|
|
|
|
|
|
|
|
|
Financing income
(expenses), net
|
|
(2,813)
|
|
521
|
|
6
|
|
602
|
|
|
|
|
|
|
|
|
|
Loss before taxes on
income
|
|
(29,754)
|
|
(30,432)
|
|
(3,776)
|
|
(8,090)
|
Taxes on income (tax
benefit)
|
|
90
|
|
13
|
|
45
|
|
(6)
|
|
|
|
|
|
|
|
|
|
Loss
|
|
$
(29,844)
|
|
$
(30,445)
|
|
$
(3,821)
|
|
$
(8,084)
|
|
|
|
|
|
|
|
|
|
Attributable
to:
|
|
|
|
|
|
|
|
|
Equity holders of the
Company
|
|
(26,638)
|
|
(27,793)
|
|
(2,998)
|
|
(7,371)
|
Non-controlling
interests
|
|
(3,206)
|
|
(2,652)
|
|
(823)
|
|
(713)
|
|
|
|
|
|
|
|
|
|
|
|
$
(29,844)
|
|
$
(30,445)
|
|
$
(3,821)
|
|
$
(8,084)
|
|
|
|
|
|
|
|
|
|
Basic and diluted loss
per share,
attributable to equity holders of the Company
|
|
$ (0.65)
|
|
$
(0.69)
|
|
$
(0.07)
|
|
$
(0.18)
|
|
|
|
|
|
|
|
|
|
Weighted average number
of shares
used in computing basic and diluted loss per share
|
|
41,210,184
|
|
40,433,303
|
|
41,234,438
|
|
41,169,222
|
|
|
|
|
|
|
|
|
|
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
U.S. dollars in
thousands
|
|
|
|
Year
ended
December
31,
|
|
Three months
ended
December
31,
|
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
|
|
(Unaudited)
|
|
(Audited)
|
|
(Unaudited)
|
Cash flows from
operating activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss
|
|
$
(29,844)
|
|
$
(30,445)
|
|
$
(3,821)
|
|
$
(8,084)
|
|
|
|
|
|
|
|
|
|
Adjustments to
reconcile loss to net cash used in
operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments to the profit or loss items:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation
|
|
1,513
|
|
1,302
|
|
396
|
|
317
|
Amortization of
Intangible assets
|
|
1,067
|
|
932
|
|
245
|
|
235
|
Share-based
compensation
|
|
1,186
|
|
2,609
|
|
291
|
|
737
|
Revaluation of
convertible SAFE
|
|
114
|
|
-
|
|
114
|
|
-
|
Net financing expenses
(income)
|
|
2,979
|
|
(884)
|
|
(149)
|
|
(733)
|
Decrease (increase) in
accrued bank interest
|
|
7
|
|
11
|
|
-
|
|
(4)
|
Loss from derecognition
of property, plant and
equipment
|
|
-
|
|
121
|
|
-
|
|
121
|
Taxes on income
(tax benefit)
|
|
90
|
|
13
|
|
45
|
|
(6)
|
|
|
|
|
|
|
|
|
|
|
|
6,956
|
|
4,104
|
|
942
|
|
667
|
Changes in asset and
liability items:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Decrease (increase) in
trade receivables
|
|
(67)
|
|
(59)
|
|
104
|
|
(130)
|
Decrease (increase) in
other receivables
|
|
1,113
|
|
637
|
|
670
|
|
(791)
|
Increase in
inventories
|
|
(474)
|
|
(92)
|
|
(401)
|
|
(92)
|
Increase in deferred
taxes
|
|
(94)
|
|
-
|
|
(94)
|
|
-
|
Increase (decrease) in
trade payables
|
|
(469)
|
|
625
|
|
131
|
|
(362)
|
Increase (decrease) in
employees and payroll accruals
|
|
(675)
|
|
127
|
|
(337)
|
|
301
|
Increase in other
payables
|
|
48
|
|
290
|
|
634
|
|
266
|
Increase (decrease) in
deferred revenues and
other advances
|
|
(153)
|
|
128
|
|
(338)
|
|
175
|
|
|
|
|
|
|
|
|
|
|
|
(771)
|
|
1,656
|
|
369
|
|
(633)
|
|
|
|
|
|
|
|
|
|
Cash received (paid)
during the period for:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest
received
|
|
186
|
|
297
|
|
68
|
|
52
|
Interest
paid
|
|
(165)
|
|
(315)
|
|
191
|
|
(90)
|
Taxes (paid) received,
net
|
|
(40)
|
|
(13)
|
|
(6)
|
|
6
|
|
|
|
|
|
|
|
|
|
Net cash used in
operating activities
|
|
$
(23,678)
|
|
$
(24,716)
|
|
$
(2,257)
|
|
$
(8,082)
|
CONSOLIDATED
STATEMENTS OF CASH FLOWS
|
U.S. dollars in
thousands
|
|
|
|
Year
ended
December
31,
|
|
Three months
ended
December
31,
|
|
|
2022
|
|
2021
|
|
2022
|
|
2021
|
|
|
(Unaudited)
|
|
(Audited)
|
|
(Unaudited)
|
Cash flows from
investing activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of property,
plant and equipment
|
|
$
(1,171)
|
|
$
(847)
|
|
$
(199)
|
|
$
(260)
|
Proceeds from sale of
marketable securities
|
|
12,356
|
|
4,395
|
|
4
|
|
3,378
|
Purchase of marketable
securities
|
|
(911)
|
|
(23,114)
|
|
(252)
|
|
(1,710)
|
Withdrawal from
(investment in) bank deposits, net
|
|
3,000
|
|
(1,000)
|
|
-
|
|
600
|
|
|
|
|
|
|
|
|
|
Net cash provided by
(used in) investing activities
|
|
13,274
|
|
(20,566)
|
|
(447)
|
|
2,008
|
|
|
|
|
|
|
|
|
|
Cash flows from
financing activities
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance
of ordinary shares, net of
issuance expenses
|
|
21
|
|
29,582
|
|
21
|
|
-
|
Proceeds from issuance
of convertible SAFE
|
|
10,000
|
|
-
|
|
-
|
|
-
|
Proceeds from exercise
of options
|
|
7
|
|
484
|
|
-
|
|
8
|
Repayment of lease
liability
|
|
(803)
|
|
(580)
|
|
(437)
|
|
(143)
|
Proceeds from
government grants
|
|
149
|
|
824
|
|
60
|
|
32
|
Repayment of government
grants
|
|
(31)
|
|
(34)
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
Net cash provided by
(used in) financing activities
|
|
9,343
|
|
30,276
|
|
(356)
|
|
(103)
|
|
|
|
|
|
|
|
|
|
Exchange rate
differences - cash and cash equivalent
balances
|
|
(2,284)
|
|
1,102
|
|
180
|
|
869
|
|
|
|
|
|
|
|
|
|
Decrease in cash
and cash equivalents
|
|
(3,345)
|
|
(13,904)
|
|
(2,880)
|
|
(5,308)
|
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents beginning of the period
|
|
32,325
|
|
46,229
|
|
31,860
|
|
37,633
|
|
|
|
|
|
|
|
|
|
Cash and cash
equivalents end of the period
|
|
$ 28,980
|
|
$
32,325
|
|
$
28,980
|
|
$
32,325
|
|
|
|
|
|
|
|
|
|
Significant non-cash
activities
|
|
|
|
|
|
|
|
|
Acquisition of
property, plant and equipment
|
|
$
74
|
|
$
32
|
|
$
74
|
|
$
32
|
Increase of
right-of-use-asset recognized with
corresponding lease liability
|
|
$
90
|
|
$
841
|
|
$
71
|
|
$
53
|
Exercise of pre-funded
warrants
|
|
$
-
|
|
$
4,365
|
|
$
-
|
|
$
-
|
|
|
|
|
|
|
|
|
|
Logo: https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original
content:https://www.prnewswire.com/news-releases/evogene-reports-fourth-quarter-and-full-year-2022-financial-results-301767788.html
SOURCE Evogene